| abstract |
There is an increased risk of optineurin-related glaucoma or optineurin-related glaucoma testing the sample for the presence of glaucoma or specific mutations associated with an increased risk of glaucoma in the gene optineurin Or a method for diagnosing its absence is described. Also described are methods of testing a sample for the presence of denaturation in expression of the optineurin polypeptide, and methods of testing the sample for the presence of alteration of the activity of the optineurin polypeptide. A method for treating glaucoma using an optineurin therapeutic agent is also described. |